Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanislas Pol

Showing results (91-100 of 441) with videos related to

Pageof 45
Sort By:
Gastroenterologie Clinique Et Biologique|December 17, 2002
[Hepatitis B virus genotypes: clinical, epidemiological and therapeutic implications]Philippe Halfon, Stanislas Pol, Marc Bourlière, et al.
Alimentary Pharmacology & Therapeutics|December 31, 2024
Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10-Year French Nationwide Cohort StudyLaurent Lam, Marc Bourlière, Stanislas Pol, et al.
Drugs|July 12, 2023
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort StudyLaurent Lam, Stanislas Pol, Ariel Cohen, et al.
Frontiers in Immunology|July 2, 2021
Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver FibrosisDaria M Kartasheva-Ebertz, Stanislas Pol, Sylvie Lagaye
Gastroenterologie Clinique Et Biologique|January 2, 2008
[Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease]Marc Bourlière, Jean Charles Duclos-Vallée, Stanislas Pol
Hepatology (Baltimore, Md.)|May 13, 2009
Human immunodeficiency virus-associated obliterative portopathy underlies unexplained aminotransferase elevations under antiretroviralsVincent O Mallet, Anaïs Vallet-Pichard, Stanislas Pol
Gastroenterologie Clinique Et Biologique|July 5, 2003
[Liver and ageing: clinical aspects]Arnaud Plat, Nelly Youssef, Nicole Brousse, et al.
Plos One|June 12, 2008
Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotypeHendy Abdoul, Vincent Mallet, Stanislas Pol, et al.
The American Journal of Gastroenterology|March 18, 2008
Response to Schiano et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIVVincent O Mallet, Marie-Pierre Bralet, Stanislas Pol
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
Is elimination of HCV realistic by 2030: FranceStanislas Pol, Loriane Lair-Mehiri, Anaïs Vallet-Pichard
Pageof 45

Showing results (91-100 of 441) with videos related to

Sort By:
Pageof 45
Gastroenterologie Clinique Et Biologique|December 17, 2002
[Hepatitis B virus genotypes: clinical, epidemiological and therapeutic implications]Philippe Halfon, Stanislas Pol, Marc Bourlière, et al.
Alimentary Pharmacology & Therapeutics|December 31, 2024
Impact of Nucleos(t)ide Analogs on Major Clinical Outcomes in Patients With Chronic Hepatitis B: A 10-Year French Nationwide Cohort StudyLaurent Lam, Marc Bourlière, Stanislas Pol, et al.
Drugs|July 12, 2023
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort StudyLaurent Lam, Stanislas Pol, Ariel Cohen, et al.
Frontiers in Immunology|July 2, 2021
Retinoic Acid: A New Old Friend of IL-17A in the Immune Pathogeny of Liver FibrosisDaria M Kartasheva-Ebertz, Stanislas Pol, Sylvie Lagaye
Gastroenterologie Clinique Et Biologique|January 2, 2008
[Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease]Marc Bourlière, Jean Charles Duclos-Vallée, Stanislas Pol
Hepatology (Baltimore, Md.)|May 13, 2009
Human immunodeficiency virus-associated obliterative portopathy underlies unexplained aminotransferase elevations under antiretroviralsVincent O Mallet, Anaïs Vallet-Pichard, Stanislas Pol
Gastroenterologie Clinique Et Biologique|July 5, 2003
[Liver and ageing: clinical aspects]Arnaud Plat, Nelly Youssef, Nicole Brousse, et al.
Plos One|June 12, 2008
Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotypeHendy Abdoul, Vincent Mallet, Stanislas Pol, et al.
The American Journal of Gastroenterology|March 18, 2008
Response to Schiano et al. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIVVincent O Mallet, Marie-Pierre Bralet, Stanislas Pol
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
Is elimination of HCV realistic by 2030: FranceStanislas Pol, Loriane Lair-Mehiri, Anaïs Vallet-Pichard
Pageof 45